Journal Watch · Journal of Medicinal Chemistry · 2026

A Hypoxia-Activated Photomolecular Glue with Synergistic Cyclin K Degradation and Phototherapy for Cancer Treatment.

It is expected to be generalizable to other molecular glues and phototherapeutic agents.

Li S, Tian Z, Ma Y et al.Journal of Medicinal Chemistry3 min readPharma relevance 50/100

DOI: 10.1021/acs.jmedchem.6c01039PMID: 42233232Study type: research study

TL;DR

It is expected to be generalizable to other molecular glues and phototherapeutic agents.

Key findings

  • In vivo, <b>BNNC</b> exhibited potent tumor growth inhibition with excellent biosafety and biocompatibility.
  • This intelligent design framework significantly improves the therapeutic efficacy and selectivity of molecular glues.
  • It is expected to be generalizable to other molecular glues and phototherapeutic agents.

What they did

Herein, we developed <b>BNNC</b>, a photomolecular glue that releases Cyclin K molecular glue <b>(</b><i><b>R</b></i><b>)-CR8</b> and phototherapeutic agent <b>BSS-Et</b> in hypoxic tumor microenvironments, thereby enhancing tumor selectivity. Network pharmacology and Western blotting analysis demonstrated that the combination of <b>(</b><i><b>R</b></i><b>)-CR8</b> and <b>BSS-Et</b> synergistically enhances DNA damage and apoptosis in breast cancer cells compared to either monotherapy.

Full abstract (original)

Background: Cyclin K is overexpressed in multiple tumors and plays critical roles in tumorigenesis, making it a promising therapeutic target. Although the antitumor potential of Cyclin K-targeting molecular glues, their clinical application is limited by insufficient efficacy and tumor selectivity.

What they did: Herein, we developed <b>BNNC</b>, a photomolecular glue that releases Cyclin K molecular glue <b>(</b><i><b>R</b></i><b>)-CR8</b> and phototherapeutic agent <b>BSS-Et</b> in hypoxic tumor microenvironments, thereby enhancing tumor selectivity. Network pharmacology and Western blotting analysis demonstrated that the combination of <b>(</b><i><b>R</b></i><b>)-CR8</b> and <b>BSS-Et</b> synergistically enhances DNA damage and apoptosis in breast cancer cells compared to either monotherapy.

Results & conclusions: In vivo, <b>BNNC</b> exhibited potent tumor growth inhibition with excellent biosafety and biocompatibility. This intelligent design framework significantly improves the therapeutic efficacy and selectivity of molecular glues. It is expected to be generalizable to other molecular glues and phototherapeutic agents.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c01039 · PubMed 42233232.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

It is expected to be generalizable to other molecular glues and phototherapeutic agents.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. Herein, we developed <b>BNNC</b>, a photomolecular glue that releases Cyclin K molecular glue <b>(</b><i><b>R</b></i><b>)-CR8</b> and phototherapeutic agent <b>BSS-Et</b> in hypoxic tumor microenvironments, thereby enhancing tumor selectivity.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c01039. PubMed ID: 42233232. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li S, Tian Z, Ma Y et al.. A Hypoxia-Activated Photomolecular Glue with Synergistic Cyclin K Degradation and Phototherapy for Cancer Treatment.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c01039.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-hypoxia-activated-photomolecular-glue-with-synergistic-cyclin-k-degrad-c01039/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides